{"generic":"Etonogestrel","drugs":["Etonogestrel","Implanon","Nexplanon"],"mono":{"0":{"id":"928569-s-0","title":"Generic Names","mono":"Etonogestrel"},"1":{"id":"928569-s-1","title":"Dosing and Indications","sub":{"0":{"id":"928569-s-1-4","title":"Adult Dosing","mono":"<b>Contraception, Female:<\/b> insert 1 single rod, 68-mg implant SUBDERMALLY in the upper part, inner side of the non-dominant arm; remove the implant no later than 3 years after insertion; may replace with a new one if continued contraception is desired "},"1":{"id":"928569-s-1-5","title":"Pediatric Dosing","mono":"clinical studies have not been conducted in women less than 18 years of age; safety and efficacy are expected to be identical for postpubertal adolescents; use before menarche is not indicated "},"3":{"id":"928569-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Contraception, Female<br\/>"}}},"3":{"id":"928569-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928569-s-3-9","title":"Contraindications","mono":"<ul><li>abnormal, undiagnosed genital bleeding<\/li><li>breast cancer, known, suspected, or personal history of<\/li><li>hepatic tumors, benign or malignant<\/li><li>hypersensitivity to etonogestrel or any component of the product<\/li><li>liver disease, active<\/li><li>pregnancy, known or suspected<\/li><li>progestin-sensitive cancer, history or current<\/li><li>thrombosis or thromboembolic disorders, history or current<\/li><\/ul>"},{"id":"928569-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- increased risk of myocardial infarction; monitoring recommended and removal may be required<\/li><li>-- fluid retention may occur; monitoring recommended in women with conditions that might be aggravated by fluid retention<\/li><li>-- use not recommended in women with past history of hypertension related diseases<\/li><li>-- hypertension may occur; monitoring recommended and removal may be necessary<\/li><li>Endocrine and Metabolic:<\/li><li>-- monitoring recommended in patients who develop breast nodules and in patients with a family history of breast cancer<\/li><li>-- changes in serum glucose levels or insulin resistance may occur; monitoring recommended in patients with diabetes or prediabetes<\/li><li>-- use cautiously in patients with hyperlipidemia as LDL levels may increase; monitoring recommended<\/li><li>-- weight gain may occur<\/li><li>Gastrointestinal:<\/li><li>-- gallbladder disease may occur<\/li><li>Hematologic:<\/li><li>-- increased risk of thromboembolism during postpartum period; initiate no sooner than 21 days after delivery<\/li><li>-- increased risk of deep venous thrombotic events (ie, venous thromboembolism, DVT); monitoring recommended and removal may be required<\/li><li>Hepatic:<\/li><li>-- hepatic dysfunction may occur; removal may be necessary<\/li><li>-- impaired liver function may result in poor metabolism of drug<\/li><li>-- remove implant if jaundice develops<\/li><li>Neurologic:<\/li><li>-- increased risk of stroke; monitoring recommended and removal may be required<\/li><li>Ophthalmic:<\/li><li>-- use cautiously in contact lens wearers as drug may cause visual changes or decrease lens tolerance; monitoring recommended<\/li><li>-- evaluate for retinal vein thrombosis immediately if unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions develop<\/li><li>Psychiatric:<\/li><li>-- use cautiously in patients with a history of depression; monitoring recommended and removal may be required<\/li><li>Renal:<\/li><li>-- use not recommended in women with history of renal disease<\/li><li>Reproductive:<\/li><li>-- ectopic pregnancy may occur<\/li><li>-- return of fertility is rapid following removal; if continued contraception is desired, resume contraceptive therapy immediately after implant removal<\/li><li>-- menstrual bleeding abnormalities, including changes in frequency and intensity or amenorrhea, may occur<\/li><li>-- ovarian cysts may occur and may require surgery<\/li><li>Respiratory:<\/li><li>-- increased risk of pulmonary embolism; monitoring recommended and removal may be required<\/li><li>Other:<\/li><li>-- complications of insertion and removal may occur; should be inserted subdermally and palpated immediately after insertion<\/li><li>-- deep insertions may cause neural or vascular injury or result in migration of the implant<\/li><li>-- difficult or impossible removal may occur with improper or deep insertion, non-palpable implants, migrated implants, or implants encased in fibrous tissue; surgery may be required<\/li><li>-- expulsion of the implant may occur with incomplete insertion or infection<\/li><li>-- consider removal of the implant during periods of immobilization due to surgery or illness<\/li><\/ul>"},{"id":"928569-s-3-11","title":"Pregnancy Category","mono":"Fetal risk cannot be ruled out. (TH)<br\/>"},{"id":"928569-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"928569-s-4","title":"Drug Interactions","sub":[{"id":"928569-s-4-13","title":"Contraindicated","mono":"<ul>Tranexamic Acid (probable)<\/ul>"},{"id":"928569-s-4-14","title":"Major","mono":"<ul><li>Aripiprazole (theoretical)<\/li><li>Carbamazepine (probable)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Fentanyl (theoretical)<\/li><li>Isotretinoin (theoretical)<\/li><li>Theophylline (theoretical)<\/li><li>Ulipristal (established)<\/li><\/ul>"},{"id":"928569-s-4-15","title":"Moderate","mono":"<ul><li>Alprazolam (probable)<\/li><li>Amprenavir (probable)<\/li><li>Aprepitant (probable)<\/li><li>Atazanavir (probable)<\/li><li>Bacampicillin (probable)<\/li><li>Betamethasone (probable)<\/li><li>Bexarotene (probable)<\/li><li>Bosentan (probable)<\/li><li>Colesevelam (probable)<\/li><li>Cyclosporine (probable)<\/li><li>Delavirdine (probable)<\/li><li>Efavirenz (probable)<\/li><li>Etravirine (probable)<\/li><li>Fosamprenavir (established)<\/li><li>Fosaprepitant (probable)<\/li><li>Fosphenytoin (probable)<\/li><li>Griseofulvin (established)<\/li><li>Lamotrigine (established)<\/li><li>Licorice (probable)<\/li><li>Modafinil (probable)<\/li><li>Mycophenolate Mofetil (probable)<\/li><li>Mycophenolic Acid (probable)<\/li><li>Nelfinavir (probable)<\/li><li>Oxcarbazepine (probable)<\/li><li>Phenobarbital (probable)<\/li><li>Phenytoin (probable)<\/li><li>Prednisolone (established)<\/li><li>Primidone (probable)<\/li><li>Rifabutin (probable)<\/li><li>Rifampin (established)<\/li><li>Rifapentine (probable)<\/li><li>Ritonavir (probable)<\/li><li>Rosuvastatin (probable)<\/li><li>Rufinamide (probable)<\/li><li>Selegiline (probable)<\/li><li>St John's Wort (established)<\/li><li>Telaprevir (established)<\/li><li>Topiramate (probable)<\/li><li>Troglitazone (probable)<\/li><li>Troleandomycin (established)<\/li><li>Voriconazole (established)<\/li><li>Warfarin (probable)<\/li><\/ul>"}]},"5":{"id":"928569-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Acne (6% to 18.5%)<\/li><li><b>Endocrine metabolic:<\/b>Weight increased (3% to 13.7%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (3% to 15%), Nausea (4% to 13.4%)<\/li><li><b>Neurologic:<\/b>Headache (4% to 25%)<\/li><li><b>Psychiatric:<\/b>Mood swings (3% to 14%)<\/li><li><b>Reproductive:<\/b>Amenorrhea (14% to 33%), Dysmenorrhea (7.2% to 10%), Menometrorrhagia (0.8% to 16%), Menorrhagia (15% to 25%), Oligomenorrhea (3.7% to 33.6%), Vaginitis (2% to 14.5%)<\/li><li><b>Respiratory:<\/b>Pharyngitis (10.5%), Upper respiratory infection (12.6%)<\/li><li><b>Other:<\/b>Implant site reaction (2.5% to 9.6%), Pain of breast (1.4% to 12.8%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Myocardial infarction<\/li><li><b>Hematologic:<\/b>Deep venous thrombosis, Thromboembolic disorder<\/li><li><b>Neurologic:<\/b>Thrombotic stroke<\/li><li><b>Reproductive:<\/b>Ruptured ectopic pregnancy<\/li><li><b>Respiratory:<\/b>Pulmonary embolism<\/li><\/ul>"},"6":{"id":"928569-s-6","title":"Drug Name Info","sub":{"0":{"id":"928569-s-6-17","title":"US Trade Names","mono":"<ul><li>Implanon<\/li><li>Nexplanon<\/li><\/ul>"},"2":{"id":"928569-s-6-19","title":"Class","mono":"<ul><li>Contraceptive, Progestin<\/li><li>Progestin<\/li><\/ul>"},"3":{"id":"928569-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"928569-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"928569-s-7","title":"Mechanism Of Action","mono":"Etonogestrel is a progestin and is the active metabolite of desogestrel. Etonogestrel inhibits ovulation, increases viscosity of the cervical mucus, and alters the endometrium.<br\/>"},"8":{"id":"928569-s-8","title":"Pharmacokinetics","sub":[{"id":"928569-s-8-23","title":"Absorption","mono":"Bioavailability: approximately 100% <br\/>"},{"id":"928569-s-8-24","title":"Distribution","mono":"Protein binding: sex hormone binding globulin, approximately 32%; albumin, 66%.<br\/>"},{"id":"928569-s-8-25","title":"Metabolism","mono":"Hepatic; by the cytochrome P450 3A4 isoenzyme; extensive <br\/>"},{"id":"928569-s-8-26","title":"Excretion","mono":"<ul><li>Renal: major<\/li><li>Fecal: minor<\/li><\/ul>"},{"id":"928569-s-8-27","title":"Elimination Half Life","mono":"Half-life: 25 hours <br\/>"}]},"9":{"id":"928569-s-9","title":"Administration","mono":"<b>Implantation<\/b><br\/><ul><li>(subdermal) all healthcare providers must receive instruction, training, and supervision (when appropriate) prior to inserting or removing the etonogestrel implant<\/li><li>(subdermal) insert the implant under aseptic conditions<\/li><li>(subdermal) insert the implant subdermally in the inner side of the upper part of the nondominant arm, about 8 to 10 cm (3 to 4 inches) above the elbow crease that overlies the groove between the biceps and triceps<\/li><li>(subdermal) palpate the implant after insertion to ensure implantation<\/li><li>(subdermal) remove the implant no later than 3 years after insertion<\/li><li>(subdermal) after removal, measure rod to ensure entire 4 cm device is recovered; if only partial implant recovered, remove all remaining sections<\/li><\/ul>"},"10":{"id":"928569-s-10","title":"Monitoring","mono":"<ul><li>pregnancy prevention indicates efficacy<\/li><li>all indicated healthcare issues; at each yearly healthcare provider visit<\/li><li>lipids; closely in women being treated for hyperlipidemias<\/li><li>blood glucose; carefully in prediabetic and diabetic women<\/li><li>breast cancer; in women with a family history of breast cancer or who develop breast nodules<\/li><li>blood pressure; yearly  and more closely in women with hypertension<\/li><li>fluid retention; in women with conditions which might be aggravated by fluid retention<\/li><li>signs and symptoms of depression; in women with a history of depressed mood.<\/li><\/ul>"},"11":{"id":"928569-s-11","title":"How Supplied","mono":"<ul><li><b>Implanon<\/b><br\/>Intradermal Implant: 68 MG<br\/><\/li><li><b>Nexplanon<\/b><br\/>Intradermal Implant: 68 MG<br\/><\/li><\/ul>"},"12":{"id":"928569-s-12","title":"Toxicology","sub":[{"id":"928569-s-12-31","title":"Clinical Effects","mono":"<b>PROGESTINS<\/b><br\/>OVERDOSE:  Rarely do acute ingestions result in obvious clinical manifestations.  CHRONIC: Most  adverse effects are related to chronic or high-dose therapy.  Headache, dizziness, irregular menses, mastalgia, bloating, depression, decreased libido, cholestatic jaundice, hepatitis, oligomenorrhea, amenorrhea and thromboembolism may occur with chronic therapy.<br\/>"},{"id":"928569-s-12-32","title":"Treatment","mono":"<b>PROGESTINS <\/b><br\/><ul><li>Support: Single acute overdoses will seldom result in toxicity.  Supportive treatment is adequate in most situations.<\/li><li>Decontamination: Gastric decontamination is probably only necessary after very large ingestions or with toxic coingestants; administer activated charcoal in these cases.<\/li><li>Monitoring of patient: CHRONIC TOXICITY: Discontinue medication and monitor for signs of toxicity and treat symptomatically.  Obtain a baseline CBC and hepatic and renal function tests in symptomatic patients.<\/li><\/ul>"},{"id":"928569-s-12-33","title":"Range of Toxicity","mono":"<b>PROGESTINS<\/b><br\/>Toxicity is unlikely following an acute overdose.  There are insufficient data reported in the literature to assess the range of toxicity in terms of mg\/kg ingested. <br\/>"}]},"13":{"id":"928569-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to practice safe sex. Drug does not prevent disease transmission.<\/li><li>Discuss potential long-term adverse effects of hormone therapy including myocardial infarction, stroke, thrombotic events, pulmonary embolism, or breast cancer.<\/li><li>This drug may cause pharyngitis, acne, weight gain, nausea, headache, vaginitis, abdominal pain, breast pain, and change in normal menstrual bleeding pattern.<\/li><li>Instruct patient to immediately report signs\/symptoms of serious cardiovascular events such as myocardial infarction, stroke, venous thrombosis, or pulmonary embolism.<\/li><li>Advise patient to immediately report unexplained lower abdominal pain or signs\/symptoms of breast cancer, depression, hepatotoxicity, or retinal vein thrombosis.<\/li><li>Tell patient to report persistent\/recurrent abnormal vaginal bleeding.<\/li><li>Patients should report any unexplained partial or complete loss of vision. In addition, patients who wear contact lenses should report visual changes or changes in lens tolerance.<\/li><li>A nonhormonal back-up method of contraception may be required for the first 7 days after implant insertion.<\/li><li>Patients should not smoke during therapy, as this increases the risk of serious cardiovascular side effects.<\/li><\/ul>"}}}